Remedy Plan Therapeutics is a privately-held, clinical-stage pharmaceutical company developing novel, hyperbolic NAMPT inhibitors. NAMPT is an enzyme that controls how cells use energy and is core to human biology. It is dysregulated in more than 20 diseases spanning oncology, autoimmunity, and metabolic disorders. Previous efforts by others to inhibit NAMPT activity resulted in severe on-target toxicities in healthy tissues, which prevented meaningful clinical activity. Remedy Plan has developed a first-in-class approach to NAMPT inhibition that never fully turns NAMPT activity off. This selectively avoids on-target toxicity in healthy tissues while still meaningfully inhibiting NAMPT activity in diseased cells.